Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti after getting a positive opinion on the drug from the EMA's human medicines
ESMO 2024 was chock full of oncological data, diverse presentations providing hope across the cancer spectrum from breast and lung to unmet needs in colorectal and bladder.